Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Achira is engaged in development and commercialization of PoC medical test kits in India
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
EBITDA before special items falls 1.3 percent to € 4.41 billion
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Subscribe To Our Newsletter & Stay Updated
